PrPSc-specific antibodies with the ability to immunodetect prion oligomers

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Tayebi, Mourad ^a   Jones, Daryl Rhys ^a   Taylor, William Alexander ^a   Stileman, Benjamin Frederick ^a   Chapman, Charlotte ^a   Zhao, Deming ^b   David, Monique ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; OLIGOMER; PRION PROTEIN; PRION PROTEIN ANTIBODY; ANTIBODY; BIOPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNODETECTION; IMMUNOREACTIVITY; MOUSE; NERVE CELL MEMBRANE; NEUROBLASTOMA CELL; NONHUMAN; SCRAPIE; ANIMAL; CATTLE; CELL LINE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; SHEEP;

MUS;

ANIMALS; ANTIBODIES; BIOPOLYMERS; CATTLE; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; PRPSC PROTEINS; SHEEP;

EID: 79956282724     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019998     Document Type: Article

References (42)

1. Haass C, Selkoe DJ, (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112.
2. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, et al. (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 20: 419-425.
3. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, et al. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 17: 1945-1947.
4. Kascsak RJ, Rubenstein R, Merz PA, Tonna-DeMasi M, Fersko R, et al. (1987) Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 61: 3688-3693.
5. Porter DD, Porter HG, Cox NA, (1973) Failure to demonstrate a humoral immune response to scrapie infection in mice. J Immunol 111: 1407-1410.
6. Zanusso G, Liu D, Ferrari S, Hegyi I, Yin X, et al. (1998) Prion protein expression in different species: analysis with a panel of new mAbs. Proc Natl Acad Sci U S A 95: 8812-8816.
7. Williamson RA, Peretz D, Smorodinsky N, Bastidas R, Serban H, et al. (1996) Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. Proc Natl Acad Sci U S A 93: 7279-7282.
8. Korth C, Stierli B, Streit P, Moser M, Schaller O, et al. (1997) Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature 390: 74-77.
9. Horiuchi M, Karino A, Furuoka H, Ishiguro N, Kimura K, et al. (2009) Generation of monoclonal antibody that distinguishes PrPSc from PrPC and neutralizes prion infectivity. Virology 394: 200-207.
10. Cordes H, Bergstrom AL, Ohm J, Laursen H, Heegaard PM, et al. (2008) Characterisation of new monoclonal antibodies reacting with prions from both human and animal brain tissues. J Immunol Methods 337: 106-120.
11. Jones M, Wight D, McLoughlin V, Norrby K, Ironside JW, et al. (2009) An antibody to the aggregated synthetic prion protein peptide (PrP106-126) selectively recognizes disease-associated prion protein (PrP) from human brain specimens. Brain Pathol 19: 293-302.
12. Polymenidou M, Moos R, Scott M, Sigurdson C, Shi YZ, et al. (2008) The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes. PLoS One 3: e3872.
13. Demart S, Fournier JG, Creminon C, Frobert Y, Lamoury F, et al. (1999) New insight into abnormal prion protein using monoclonal antibodies. Biochem Biophys Res Commun 265: 652-657.
14. Yokoyama T, Itohara S, Yuasa N, (1996) Detection of species specific epitopes of mouse and hamster prion proteins (PrPs) by anti-peptide antibodies. Arch Virol 141: 763-769.
15. Tayebi M, Collinge J, Hawke S, (2009) Unswitched immunoglobulin M response prolongs mouse survival in prion disease. J Gen Virol 90: 777-782.
16. Nakamura N, Miyamoto K, Shimokawa M, Nishida N, Mohri S, et al. (2003) Generation of antibodies against prion protein by scrapie-infected cell immunization of PrP(0/0) mice. Hybrid Hybridomics 22: 263-266.
17. Spinner DS, Kascsak RB, LaFauci G, Meeker HC, Ye X, et al. CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J Leukoc Biol 81: 1374-1385.
18. Prusiner SB, Groth D, Serban A, Koehler R, Foster D, et al. (1993) Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci U S A 90: 10608-10612.
19. Tayebi M, Enever P, Sattar Z, Collinge J, Hawke S, (2004) Disease-associated prion protein elicits immunoglobulin M responses in vivo. Mol Med 10: 104-111.
20. Curin SV, Bresjanac M, Popovic M, Pretnar HK, Galvani V, et al. (2004) Monoclonal antibody against a peptide of human prion protein discriminates between Creutzfeldt-Jacob's disease-affected and normal brain tissue. J Biol Chem 279: 3694-3698.
21. Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, et al. (2003) A prion protein epitope selective for the pathologically misfolded conformation. Nat Med 9: 893-899.
22. Jones DR, Taylor WA, Bate C, David M, Tayebi M, (2010) A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines. PLoS One 5: e9804.
23. Oesch B, Westaway D, Walchli M, McKinley MP, Kent SB, et al. (1985) A cellular gene encodes scrapie PrP 27-30 protein. Cell 40: 735-746.
24. Nishimura T, Sakudo A, Xue G, Ikuta K, Yukawa M, et al. (2008) Establishment of a new glial cell line from hippocampus of prion protein gene-deficient mice. Biochem Biophys Res Commun 377: 1047-1050.
25. Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, et al. (2010) Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Abeta oligomers. Mol Neurodegener 5: 57.
26. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489.
27. Soto C, (1999) Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches. J Mol Med 77: 412-418.
28. Conway KA, Harper JD, Lansbury PT Jr, (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39: 2552-2563.
29. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
30. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, et al. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-511.
31. Williamson RA, Peretz D, Pinilla C, Ball H, Bastidas RB, et al. (1998) Mapping the prion protein using recombinant antibodies. J Virol 72: 9413-9418.
32. Wopfner F, Weidenhofer G, Schneider R, von BA, Gilch S, et al. (1999) Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein. J Mol Biol 289: 1163-1178.
33. Beringue V, Mallinson G, Kaisar M, Tayebi M, Sattar Z, et al. (2003) Regional heterogeneity of cellular prion protein isoforms in the mouse brain. Brain 126: 2065-2073.
34. Rubenstein R, Kascsak RJ, Papini M, Kascsak R, Carp RI, et al. (1999) Immune surveillance and antigen conformation determines humoral immune response to the prion protein immunogen. J Neurovirol 5: 401-413.
35. Wadsworth JD, Hill AF, Beck JA, Collinge J, (2003) Molecular and clinical classification of human prion disease. Br Med Bull 66: 241-254.
36. Hill AF, Joiner S, Beck JA, Campbell TA, Dickinson A, et al. (2006) Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations. Brain 129: 676-685.
37. Bessen RA, Marsh RF, (1992) Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J Virol 66: 2096-2101.
38. Bessen RA, Marsh RF, (1994) Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J Virol 68: 7859-7868.
39. Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, et al. (1992) Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356: 577-582.
40. Kim JI, Kuizon S, Rubenstein R, (2003) Comparison of PrP transcription and translation in two murine myeloma cell lines. J Neuroimmunol 140: 137-142.
41. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, et al. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2: 18.
42. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.